<h3>Overview</h3> <p>The <span class="key-term" data-definition="Delhi High Court — The apex judicial body for the National Capital Territory of Delhi, whose judgments shape legal precedents on health, ethics and personal liberty (GS4: Ethics)">Delhi High Court</span> has granted permission to extract and cryopreserve the sperm of an Indian Army soldier in a persistent vegetative state, enabling his wife to pursue <span class="key-term" data-definition="In vitro fertilisation (IVF) — Assisted reproductive technology that fertilises eggs outside the body and transfers embryos back, a growing health‑policy issue in India (GS3: Health)">IVF</span> treatment. The same week, the Union Budget 2026‑27 unveiled <span class="key-term" data-definition="Biopharma SHAKTI — A five‑year, ₹10,000 crore programme aimed at building India’s biopharma infrastructure, establishing new NIPER institutes and a network of clinical‑trial sites (GS3: Economy)">Biopharma SHAKTI</span>, signalling a strategic push to position India as a global hub for <span class="key-term" data-definition="biologics — Large‑molecule therapeutics such as monoclonal antibodies, vaccines and insulin, derived from living cells and regulated differently from small‑molecule drugs (GS3: Health)">biologics</span>.</p> <h3>Key Developments</h3> <ul> <li>Delhi High Court authorises sperm extraction and cryopreservation for a soldier in a vegetative state, upholding reproductive rights and medical ethics.</li> <li>Union Budget allocates ₹10,000 crore to the <span class="key-term" data-definition="Biopharma SHAKTI — A five‑year, ₹10,000 crore programme aimed at building India’s biopharma infrastructure, establishing new NIPER institutes and a network of clinical‑trial sites (GS3: Economy)">Biopharma SHAKTI</span> programme, creating three new National Institutes for Pharmaceuticals Education and Research (<span class="key-term" data-definition="NIPER — National Institutes for Pharmaceuticals Education and Research, premier centres for drug‑discovery and biomanufacturing training (GS3: Economy)">NIPER</span>) and 1,000 accredited clinical‑trial sites.</li> <li>January 2026 – Biologics × 3DCC Summit merges biopharma product‑development and 3‑D cell‑culture conferences, highlighting advances in monoclonal antibodies, cell‑ and gene‑therapy platforms.</li> <li>Emphasis on production platforms: CHO (Chinese Hamster Ovary) cell lines for glycosylated therapeutics such as anti‑Müllerian hormone (AMH) assays used in IVF.</li> </ul> <h3>Important Facts</h3> <p>• <span class="key-term" data-definition="monoclonal antibodies (mAbs) — Laboratory‑produced antibodies that target specific antigens, constituting ~54 % of the global biologics market (GS3: Health)">Monoclonal antibodies</span> remain the largest segment of biologics, driving demand for advanced cell‑culture facilities.<br> • Glycosylation – the addition of sugar moieties to proteins – is essential for the activity of many therapeutic proteins; bacterial systems cannot perform human‑type glycosylation, necessitating mammalian hosts such as <span class="key-term" data-definition="CHO cell line — Chinese Hamster Ovary cells widely used for producing glycosylated therapeutic proteins; they provide human‑like post‑translational modifications (GS3: Health)">CHO cell lines</span>.<br> • Bioreactor technologies now include single‑use vessels, continuous flow systems and AI‑driven monitoring to improve yield and reduce contamination risks.<br> • Ethical concerns arise as many breakthroughs stem from publicly funded research but are commercialised at prices that limit access for low‑income groups.</p> <h3>UPSC Relevance</h3> <p>The case illustrates the intersection of <strong>law, ethics and health policy</strong> – a classic GS4 topic. Understanding <span class="key-term" data-definition="biologics — Large‑molecule therapeutics such as monoclonal antibodies, vaccines and insulin, derived from living cells and regulated differently from small‑molecule drugs (GS3: Health)">biologics</span> versus small‑molecule drugs is essential for GS3 questions on pharmaceutical policy, pricing and indigenous manufacturing. The <span class="key-term" data-definition="Biopharma SHAKTI — A five‑year, ₹10,000 crore programme aimed at building India’s biopharma infrastructure, establishing new NIPER institutes and a network of clinical‑trial sites (GS3: Economy)">Biopharma SHAKTI</span> initiative ties directly to India’s ambition to reduce import dependence, create high‑skill jobs and boost export earnings – core themes in GS3 (Economy) and GS2 (Polity) regarding government programmes.</p> <h3>Way Forward</h3> <p>To translate policy intent into tangible outcomes, India must:</p> <ul> <li>Accelerate the establishment of the three new <span class="key-term" data-definition="NIPER — National Institutes for Pharmaceuticals Education and Research, premier centres for drug‑discovery and biomanufacturing training (GS3: Economy)">NIPER</span> campuses, ensuring they are linked with industry for technology transfer.</li> <li>Strengthen regulatory frameworks for biologics, focusing on biosimilarity approval pathways, pharmacovigilance and affordable pricing.</li> <li>Promote public‑private partnerships that channel publicly funded research into affordable products, especially in reproductive health and vaccine domains.</li> <li>Invest in skill development for bioprocess engineering, AI‑enabled bioreactor monitoring and cell‑free synthesis to overcome the high‑cost barrier of mammalian‑cell production.</li> </ul> <p>By addressing these steps, India can harness its scientific talent, growing domestic demand for advanced therapeutics, and the financial thrust of <span class="key-term" data-definition="Biopharma SHAKTI — A five‑year, ₹10,000 crore programme aimed at building India’s biopharma infrastructure, establishing new NIPER institutes and a network of clinical‑trial sites (GS3: Economy)">Biopharma SHAKTI</span> to emerge as a world‑class biomanufacturing hub.</p>